ONO-AE3-208

ONO-AE3-208 is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM. ONO-AE3-208 shows less potently affects EP3, FP, and TP receptors (Ki of 30 nM, 790 nM, and 2400 nM, respectively) . ONO-AE3-208 suppresses cell invasion, migration, and metastasis of prostate cancer[1][2].

Product Specifications

CAS Number

[402473-54-5]

Product Name Alternative

AE 3-208

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Cancer-programmed cell death

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/ONO-AE3-208.html

Concentration

10mM

Purity

98.65

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

N#CC1=CC=C(C(NC(C(C2=C3C=CC=CC3=C(F)C=C2)C)=O)=C1)CCCC(O)=O

Molecular Formula

C24H21FN2O3

Molecular Weight

404.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Xu S, et al. An EP4 Antagonist ONO-AE3-208 Suppresses Cell Invasion, Migration, and Metastasis of Prostate Cancer. Cell Biochem Biophys. 2014 Apr 18.|[2]Ren Y, et al. Prostaglandin E2 mediates connecting tubule glomerular feedback. Hypertension. 2013 Dec;62 (6) :1123-8.|[3]Xu S, et al. Inhibitory effect of ONO-AE3-208 on the formation of bone metastasis of prostate cancer in mice. Zhonghua Nan Ke Xue. 2014 Aug;20 (8) :684-9.|[4]Thieme K, et al. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease. Sci Rep. 2017 Jun 13;7 (1) :3442.|[5]Kenji Kabashima, et al. The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109 (7) :883-93.